Related Experiment Video
Updated: Jul 12, 2026
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
CD34+, CD41+ acute megakaryoblastic leukemia in a dog
Steven E Suter1, William Vernau, Michael M Fry
1Department of Veterinary Surgical and Radiological Sciences, School of Veterinary Medicine, University of California-Davis, Davis, CA, USA. steven_suter@ncsu.edu
Veterinary Clinical Pathology
|September 7, 2007
Summary
This study reports the first canine case of acute megakaryoblastic leukemia (AMegL), a rare blood cancer. Diagnosis involved identifying primitive cells in blood, spleen, and lymph nodes using specific canine markers.
Area of Science:
- Veterinary Hematology
- Canine Oncology
- Immunocytochemistry
Background:
- Acute megakaryoblastic leukemia (AMegL) is a rare and aggressive hematologic malignancy.
- Diagnosis in veterinary medicine can be challenging due to limited specific markers.
- Early detection and accurate classification are crucial for prognosis.
Observation:
- A German Shepherd dog presented with anemia and thrombocytopenia.
- Cytologic examination revealed primitive round cells in spleen, lymph nodes, and peripheral blood.
- Bone marrow aspirate showed hypercellularity with immature hematopoietic cells.
Findings:
- Immunocytochemistry confirmed neoplastic cells expressed CD41 and CD34.
- Morphology and immunophenotype were consistent with acute megakaryoblastic leukemia (AMegL).
- This is the first reported canine AMegL diagnosed using anti-canine CD34 and CD41 antibodies.
Implications:
- This case highlights the utility of CD34 and CD41 in diagnosing canine AMegL.
- Improved diagnostic criteria can aid in understanding and managing this rare leukemia in dogs.
- Further research into canine megakaryoblastic leukemia is warranted.
